Podcast 17 Nov 2023How can life-saving vaccines be more affordable? Phenotypeca, a biotech business from Nottingham, UK, has been working with the Bill & Melinda Gates Foundation to produce albumin for low and middle-income countries (LMICs), offering a catalyst for making life-saving vaccines affordable globally. Global vaccine production faces several challenges. Limited availability and the high costs associated with recombinant albumin act as a barrier […] November 17, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 15 Nov 2023 Beyond oil and gas: Biotech’s significant place in the Qatar Investment Authority’s strategy Since 2020, the Qatar Investment Authority (QIA) has been taking part in important biotech fundings reaching its peak in 2021 and remaining strong in 2023. They recently led a $250 million round in the company BridgeBio specialized in transformative medicine for patients suffering from cancer or genetic diseases. This investment is not an isolated case […] November 15, 2023 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Weekly Roundup 10 Nov 2023 Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs You are reading Labiotech’s weekly roundup of the latest biotech news. Korro Bio and Frequency Therapeutics close merger Last Friday, Korro Bio announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio. The combined company will now operate under the name Korro Bio, Inc. […] November 10, 2023 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 2 Nov 2023 How French pharma giant Sanofi is betting big on AI The benefits of artificial intelligence (AI) in shaping clinical research and trials have given rise to many new AI-driven biotech startups. According to a recent report, the number of AI companies involved in drug discovery and development increased from 62 in 2011 to 400 in 2022. This AI-driven transformation is catching the attention of big pharma […] November 2, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 28 Sep 2023 Obesity drug success sparks biotech buying spree The last few months have seen the obesity drug market soar, after new weight loss and diabetes drugs like Novo Nordisk’s Wegovy and Ozempic took the world by storm with their incredible efficacy at inducing weight loss. These new drugs belong to a class of medications called GLP-1 analogs (or incretin-based therapies), which work by […] September 28, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2023 Rebuilding relations: U.K. rejoins Horizon Europe to boost funding opportunities The U.K. is rejoining the European Union’s (EU’s) $100 billion research program Horizon Europe, after being locked out of the deal amid post Brexit tensions for more than two years. This comes after months of negotiations between the U.K. government and the EU, in an attempt to broaden opportunities for researchers in the U.K.. British […] September 18, 2023 - 5 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 15 Sep 2023Beyond Biotech podcast 63 – Fighting cancer with STRIs This week’s podcast is sponsored by Vetter. On this week’s episode, we have a conversation with Steve Worland, CEO of eFFECTOR Therapeutics. eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of cancer drugs referred to as STRIs (selective translation regulation inhibitors). eFFECTOR’s STRI product candidates target the eIF4F complex and […] September 15, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2023 Roche and Alnylam to work on RNAi therapeutic to treat hypertension Roche has announced a partnership with Alnylam to develop and commercialize zilebesiran, an investigational RNAi therapeutic currently in phase 2 for the treatment of hypertension. Hypertension affects more than 1.2 billion adults worldwide and is the main, independent, preventable risk factor for death and disability, with approximately 80% of the adults with hypertension worldwide not […] July 25, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 Mage Biologics created to develop oral antibody therapy for ulcerative colitis TVM Capital Life Science and specialty pharma company Tillotts Pharma are to jointly invest up to $28 million in a newly formed U.S.-based biotechnology company, Mage Biologics Inc. TVM will invest with its TVM Life Science Innovation II SCSp (TVM LSI II) fund and will provide strategic advice to Mage Bio. Mage Bio is the […] July 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 Seven pharma companies form alliance to prepare for future pandemics Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […] July 20, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2023 Boost for Charcot-Marie-Tooth patients as Novartis acquires DTx Pharma DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its fatty acid ligand conjugated oligonucleotide (FALCON) platform, has been acquired by Novartis. The FALCON platform enables the delivery and activity of small interfering RNA (siRNA) therapeutics to tissues beyond the liver, enhancing biodistribution and cellular uptake. DTx Pharma’s lead […] July 18, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2023 FDA approves Beyfortus ahead of 2023-24 RSV season The U.S. Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The approval also covers children up to 24 months of age who remain vulnerable to severe […] July 18, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email